The Technical AnalystExchange: STO Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Probi AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.44% SEK205.00
America/New_York / 17 mai 2024 @ 07:51
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 335.79 mill |
| EPS: | -0.0400 |
| P/E: | -5 125.00 |
| Earnings Date: | Jul 16, 2024 |
| SharesOutstanding: | 11.39 mill |
| Avg Daily Volume: | 0.0005 mill |
| RATING 2024-05-17 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5 125.00 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -212.59x |
| Company: PE -5 125.00 | industry: PE 24.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK259.90 (26.78%) SEK54.90 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 196.69 - 213.31 ( +/- 4.05%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | SEK205.00 (-1.44% ) |
| Volume | 0.0001 mill |
| Avg. Vol. | 0.0005 mill |
| % of Avg. Vol | 12.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PROB.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PROB.ST
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.